Suppr超能文献

苯磺酰胺类似物作为 NLRP3 炎性小体抑制剂的结构见解:设计、合成与生物学特征。

Structural Insights of Benzenesulfonamide Analogues as NLRP3 Inflammasome Inhibitors: Design, Synthesis, and Biological Characterization.

出版信息

J Med Chem. 2018 Jun 28;61(12):5412-5423. doi: 10.1021/acs.jmedchem.8b00733. Epub 2018 Jun 18.

Abstract

NLRP3 inflammasome plays critical roles in a variety of human diseases and represents a promising drug target. In this study, we established the in vivo functional activities of JC124, a previously identified NLRP3 inflammasome inhibitor from our group, in mouse models of Alzheimer's disease and acute myocardial infarction. To understand the chemical space of this lead structure, a series of analogues were designed, synthesized, and biologically characterized. The results revealed the critical roles of the two substituents on the benzamide moiety of JC124. On the other hand, modifications on the sulfonamide moiety of JC124 are well tolerated. Two new lead compounds, 14 and 17, were identified with improved inhibitory potency (IC values of 0.55 ± 0.091 and 0.42 ± 0.080 μM, respectively). Further characterization confirmed their selectivity and in vivo target engagement. Collectively, the results strongly encourage further development of more potent analogues based on this chemical scaffold.

摘要

NLRP3 炎性小体在多种人类疾病中发挥着关键作用,是一个很有前途的药物靶点。在这项研究中,我们在阿尔茨海默病和急性心肌梗死的小鼠模型中建立了我们之前从我们的团队中鉴定出的 NLRP3 炎性小体抑制剂 JC124 的体内功能活性。为了了解该先导结构的化学空间,设计、合成并对一系列类似物进行了生物学特征分析。结果揭示了 JC124 苯甲酰胺部分的两个取代基的关键作用。另一方面,JC124 磺酰胺部分的修饰是可以耐受的。发现了两种新的先导化合物 14 和 17,它们具有改善的抑制活性(IC 值分别为 0.55±0.091 和 0.42±0.080 μM)。进一步的特性分析证实了它们的选择性和体内靶标结合。总的来说,这些结果强烈鼓励基于该化学结构进一步开发更有效的类似物。

相似文献

1
Structural Insights of Benzenesulfonamide Analogues as NLRP3 Inflammasome Inhibitors: Design, Synthesis, and Biological Characterization.
J Med Chem. 2018 Jun 28;61(12):5412-5423. doi: 10.1021/acs.jmedchem.8b00733. Epub 2018 Jun 18.
2
4
Design, Synthesis, and Evaluation of Acrylamide Derivatives as Direct NLRP3 Inflammasome Inhibitors.
ChemMedChem. 2016 Aug 19;11(16):1790-803. doi: 10.1002/cmdc.201600055. Epub 2016 Mar 17.
5
Discovery of Second-Generation NLRP3 Inflammasome Inhibitors: Design, Synthesis, and Biological Characterization.
J Med Chem. 2019 Nov 14;62(21):9718-9731. doi: 10.1021/acs.jmedchem.9b01155. Epub 2019 Oct 31.
6
Discovery of dronedarone and its analogues as NLRP3 inflammasome inhibitors with potent anti-inflammation activity.
Bioorg Med Chem Lett. 2021 Aug 15;46:128160. doi: 10.1016/j.bmcl.2021.128160. Epub 2021 May 29.
7
Novel Isoalantolactone-Based Derivatives as Potent NLRP3 Inflammasome Inhibitors: Design, Synthesis, and Biological Characterization.
J Med Chem. 2024 May 9;67(9):7516-7538. doi: 10.1021/acs.jmedchem.4c00357. Epub 2024 Apr 30.
9
Discovery of chalcone analogues as novel NLRP3 inflammasome inhibitors with potent anti-inflammation activities.
Eur J Med Chem. 2021 Jul 5;219:113417. doi: 10.1016/j.ejmech.2021.113417. Epub 2021 Apr 1.

引用本文的文献

2
6
Inflammasomes and idiopathic inflammatory myopathies.
Front Immunol. 2024 Dec 11;15:1449969. doi: 10.3389/fimmu.2024.1449969. eCollection 2024.
7
Functional Characterization of an Arylsulfonamide-Based Small-Molecule Inhibitor of the NLRP3 Inflammasome.
ACS Chem Neurosci. 2024 Oct 2;15(19):3576-3586. doi: 10.1021/acschemneuro.4c00512. Epub 2024 Sep 19.
8
Therapeutic Targets in Innate Immunity to Tackle Alzheimer's Disease.
Cells. 2024 Aug 26;13(17):1426. doi: 10.3390/cells13171426.
9
Characterization of a small molecule inhibitor of the NLRP3 inflammasome and its potential use for acute lung injury.
Bioorg Chem. 2024 Sep;150:107562. doi: 10.1016/j.bioorg.2024.107562. Epub 2024 Jun 17.
10
NLRP3/1-mediated pyroptosis: beneficial clues for the development of novel therapies for Alzheimer's disease.
Neural Regen Res. 2024 Nov 1;19(11):2400-2410. doi: 10.4103/1673-5374.391311. Epub 2023 Dec 21.

本文引用的文献

1
Microglia-derived ASC specks cross-seed amyloid-β in Alzheimer's disease.
Nature. 2017 Dec 20;552(7685):355-361. doi: 10.1038/nature25158.
3
NLRP3 Inflammasome Inhibitor Ameliorates Amyloid Pathology in a Mouse Model of Alzheimer's Disease.
Mol Neurobiol. 2018 Mar;55(3):1977-1987. doi: 10.1007/s12035-017-0467-9. Epub 2017 Mar 2.
4
The NLRP3 and NLRP1 inflammasomes are activated in Alzheimer's disease.
Mol Neurodegener. 2016 Mar 3;11:23. doi: 10.1186/s13024-016-0088-1.
5
Inhibition of the NLRP3 inflammasome limits the inflammatory injury following myocardial ischemia-reperfusion in the mouse.
Int J Cardiol. 2016 Apr 15;209:215-20. doi: 10.1016/j.ijcard.2016.02.043. Epub 2016 Feb 4.
7
NEK7 is an essential mediator of NLRP3 activation downstream of potassium efflux.
Nature. 2016 Feb 18;530(7590):354-7. doi: 10.1038/nature16959. Epub 2016 Jan 27.
8
NLRP3 activation and mitosis are mutually exclusive events coordinated by NEK7, a new inflammasome component.
Nat Immunol. 2016 Mar;17(3):250-8. doi: 10.1038/ni.3333. Epub 2015 Dec 7.
9
NLRP3 inflammasome and its inhibitors: a review.
Front Pharmacol. 2015 Nov 5;6:262. doi: 10.3389/fphar.2015.00262. eCollection 2015.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验